Find Academic Supervisors

• Immunology
• Autoimmunity
• Gene Therapy
• +5 more

Dr Graham Wright is an Associate Professor in Immunology and Associate Dean of Research and Innovation at the School of Applied Sciences, Edinburgh Napier University. He holds a BSc (Hons) in Immunology from the University of Glasgow and a PhD from University College London, focusing on cell therapy for rheumatoid arthritis. His research interests span autoimmunity, gene therapies, and cellular therapies, with collaborations in liver transplantation, vascular healing, and bone disease. He has received grants from bodies like the Chief Scientist Office and Wellcome Trust, and his work includes developing regulatory T-cell therapies for autoimmune diseases. Wright is actively involved in academic leadership, including founding the Early Career Lecturers in Bioscience Forum, and has contributed to teaching innovations emphasizing experiential learning. His awards include a Scottish Knowledge Exchange Award nomination and Best Presentation at the Arthritis Research UK conference. Education: BSc (Hons) Immunology, University of Glasgow PhD in Immunology, University College London (2009) Research Interests: Wright’s work centers on manipulating the immune system to treat diseases like rheumatoid arthritis and multiple sclerosis. Key areas include adoptive T-cell therapy, antigen-specific regulatory T-cell engineering, and immune modulation in transplantation. He collaborates on projects involving liver transplant outcomes, vascular healing, and bone turnover in aging. Grants and Projects: £229,020 from the Chief Scientist Office (2021–2024) for regulatory T-cell therapy in rheumatoid arthritis £30,000 ENU Development Trust grant (2018–2022) for osteoarthritis research with Guangzhou Medical University Wellcome Trust Pathfinder Award (2015) for multiple sclerosis TCR therapy Awards: Scottish Knowledge Exchange Award Nomination (2019) Best Presentation, Arthritis Research UK Fellows Conference Teaching and Leadership: Wright chairs conferences on bioscience education and promotes early-career academic development. He has published on fostering student engagement and authored articles on academic challenges, including a 2020 The Biologist piece on navigating lecturing roles.

Yufang ShiView profile

Professor

• Mesenchymal stromal/stem cells (MSCs) and immune regulation
• MSCs and tumor microenvironment
• Activation-induced cell death (AICD) in T cells
• +3 more

Dr. Yufang Shi is a tenured Professor at the University of Rome Tor Vergata since 2019, serving as Secretary of the TOR Centre of Excellence. He also holds leadership roles at Soochow University (Vice President of its First Affiliated Hospital and Director of Translational Medicine Institutes since 2014) and Shanghai Institutes for Biological Sciences, CAS (Professor since 2008). His career spans institutions in North America, China, and Europe. Professor, University of Rome Tor Vergata (2019-present) Vice President, First Affiliated Hospital of Soochow University (2014-present) Director, Soochow University Institutes for Translational Medicine (2014-present) Editor-in-Chief, Cell Death & Disease (2010-present) Dr. Shi's research focuses on immune regulation by mesenchymal stromal/stem cells (MSCs) , including their role in tumor microenvironments and inflammatory disease therapies. He pioneered the "inflammation licensing" and "cell empowerment" theories for MSC-based treatments, with groundbreaking work on T cell apoptosis, opioid-induced immunosuppression, and neuro-immune interactions. His publications in Nature , Science , and Cell journals reveal MSC plasticity in immunomodulation (2014), species-specific mechanisms of MSC immunosuppression (2009), and tumor-MSC-macrophage interactions (2012). Articles consistently address apoptosis pathways , inflammatory signaling , and metabolic reprogramming in immune cells. Scientific accolades include: 2019 - Distinguished Professor, University of Rome Tor Vergata 2016 - Excellence in Translational Stem Cell Research Award 2012 - Excellence Award, All-China Federation of Overseas Chinese 1999 - Outstanding Young Scholar, Chinese Natural Science Foundation As policy advisor and journal editor, he shaped China's 973 National Research Plan on Reproduction and Development (2010-2019) and led international collaborations between European and Chinese institutions. He has organized 12 global conferences and serves on PhD committees at Tor Vergata since 2015.

Noelia LanderView profile

Assistant Professor

• Molecular Parasitology
• Trypanosoma cruzi
• Chagas Disease
• +9 more

Noelia Lander is an Assistant Professor at the University of Cincinnati's Department of Biological Sciences. Her research focuses on signal transduction pathways in Trypanosoma cruzi , the parasite responsible for Chagas disease. She pioneered CRISPR/Cas9 genome editing methods in this organism, enabling studies of calcium and cAMP signaling pathways critical for parasite survival and pathogenesis. Education: B.S. (Biology, Universidad Simón Bolívar, 2002), M.S. (Biological Sciences, Universidad Simón Bolívar, 2008), Ph.D. (Cellular Biology, University of Georgia, 2013). Postdoctoral training included roles at the University of Georgia and State University of Campinas. Current lab website: landerlab.uc.edu . Research interests include environmental sensing mechanisms, parasite differentiation, and drug target validation. Key contributions include identifying roles for calcium and cAMP signaling in T. cruzi 's life cycle transitions and host interactions. Recent work explores compartmentalized cAMP signals and mitochondrial Ca²⁺ regulation. Notable grants include NIH/NIAID funding for CRISPR screening of essential genes (R21AI140421, K99/R00AI137322) and a 2020 UGA Postdoctoral Research Award. Her lab's CRISPR tools have advanced studies of kinetoplastid parasites. Key achievements: Developed first CRISPR-based knockdown method for T. cruzi , discovered critical roles for mitochondrial calcium uniporter components, and identified CARP3 protein's role in cAMP signaling pathways.

Christian MetalloView profile

Professor

• Metabolic Biology
• Cancer Metabolism
• Cellular Metabolism
• +3 more

Christian Metallo, PhD, is a Professor at the Salk Institute for Biological Studies, where he leads the Molecular and Cell Biology Laboratory. His research focuses on understanding how metabolic pathways drive diseases such as cancer, diabetes, and neurodegenerative disorders. Metallo employs cutting-edge techniques like stable isotope tracing and mass spectrometry to map metabolic networks and identify therapeutic targets. Education: Bachelor of Science in Chemical Engineering, University of Pennsylvania Master of Science and PhD in Chemical and Biological Engineering, University of Wisconsin-Madison Postdoctoral Fellowship in Biological Sciences, Massachusetts Institute of Technology Research Interests: Metallo’s work investigates how cellular metabolism influences disease progression. Key areas include the role of serine/glycine metabolism in tumors, the metabolic defects linked to macular telangiectasia type 2, and lipid metabolism in obesity and fatty liver disease. His lab also develops tools like Escher-Trace to visualize metabolic flux. Publications: Over 100 peer-reviewed articles, including high-impact studies on metabolic reprogramming in cancer, drug development targeting metabolic vulnerabilities, and the interplay between immunity and metabolism. Recent work highlights metabolic dependencies in pancreatic cancer and the role of itaconate in immune responses. Awards: Recipient of prestigious awards including the Mark Foundation Endeavor Award (2022), AIMBE Fellowship (2021), and Camille & Henry Dreyfus Teacher-Scholar Award (2018). His research is funded by grants from the NIH, NSF, and industry partners. Labs & Teams: The Metallo Lab includes postdoctoral fellows, graduate students, and research scientists from diverse backgrounds in engineering, biochemistry, and immunology. Collaborations span academia and industry, focusing on translational applications of metabolic insights. The lab’s Escher-Trace software is widely used for metabolic pathway visualization.

Julie McElrathView profile

Academic

• HIV Vaccine Development
• Mucosal Immunology
• T-Cell Responses
• +4 more

Julie McElrath is a Professor at the Fred Hutchinson Cancer Research Center and holds the Joel D. Meyers Endowed Chair . She serves as Director of the Vaccine and Infectious Disease Division and Principal Investigator of the HIV Vaccine Trials Network (HVTN) Laboratory Center . Her work spans international HIV vaccine trials, mucosal immunity studies, and collaborations with institutions like the University of Washington (Department of Medicine, Global Health, and Laboratory Medicine & Pathology) and the Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD) . Education: MD, Medical University of South Carolina (1980) PhD, Medical University of South Carolina (1978) Dr. McElrath’s research focuses on multi-disciplinary approaches to HIV vaccine development, immune correlates of protection, and mucosal transmission mechanisms. Her lab investigates innate immune responses to vaccines and conducts longitudinal studies on long-term non-progressors. Recent work includes collaborations on coronavirus , malaria , and tuberculosis vaccines, leveraging systems biology tools. She leads initiatives like the Seattle HIV Vaccine Trials Unit and the Cape Town HVTN Immunology Laboratory . Her publications highlight immune profiling in HIV vaccine trials, adenovirus vector immunogenicity , and vaccine-induced antibody functions . She advocates for improving assay standardization and cross-pathogen immunity through networks like the Infectious Diseases Clinical Research Consortium (IDCRC) .

Amy AndreottiView profile

Professor

• Nuclear Magnetic Resonance
• Macromolecular Structure and Recognition
• Protein Kinases
• +7 more

Amy Andreotti holds the Roy J. Carver Chair and serves as a University Professor in the Department of Biochemistry, Biophysics, and Molecular Biology at Iowa State University. Her research focuses on structural and regulatory mechanisms of Tec family kinases like ITK and BTK, using nuclear magnetic resonance (NMR) and biochemical approaches to investigate immune signaling pathways and disease-related dysregulation. Amy Andreotti’s educational background includes: A.B. in Chemistry and Studio Art from Bowdoin College (1989) Ph.D. in Chemistry from Princeton University (1994) Postdoctoral Fellowship at Harvard University (1994–1997) Research Interests: Her work explores how structural features of Tec kinases govern their activity, with a focus on proline isomerization, interdomain interactions, and phospholipid binding. She studies these kinases’ roles in T-cell and B-cell signaling and develops targeted inhibitors to modulate their activity in diseases like chronic lymphocytic leukemia. NMR spectroscopy and structural biology are central to her methods, enabling detailed analysis of kinase conformational dynamics and substrate recognition. Publications Trends: Recent work emphasizes BTK’s clinical inhibitors and resistance mechanisms in cancer, alongside structural studies of Tec kinases. Earlier research highlighted ITK’s regulation by cyclophilin A and calmodulin, and the role of SH3-SH2 domain interactions in kinase activation. Her studies often integrate biochemical, structural, and computational methods to bridge basic and translational research. Roy J. Carver Chair (Endowed Professorship) Advising & Grants: No formal advisees are listed. While specific grants aren’t detailed, her research likely involves funding for drug development and structural biology projects. She collaborates with pharmaceutical researchers and biotechnology groups to advance therapeutic strategies targeting kinase dysfunction. Labs & Teams: Her research is conducted within the facilities of Iowa State University’s Roy J. Carver Department, leveraging resources like the Office of Biotechnology and MBB Conference Rooms. She participates in interdisciplinary initiatives such as the Stupka Research Symposium and Graduate Learning Community to foster collaborative research in structural biology and pharmacology.

• Immunology
• T Cell Biology
• CD4 T Cell Memory
• +5 more

Susan L. Swain is a distinguished Professor of Pathology at UMass Chan Medical School, holding multiple appointments across the T.H. Chan School of Medicine and Morningside Graduate School of Biomedical Sciences. Her academic journey spans over four decades, beginning at UCSD where she rose from Lecturer to Professor of Biology in Residence, followed by leadership roles as Director and President of the Trudeau Institute, before joining UMass Medical School in 2010. Dr. Swain's research focuses on the cellular and molecular mechanisms of CD4 T cell immunity, with particular emphasis on T cell memory formation, cytotoxic CD4 effectors, and age-related immune deficiencies. Her laboratory has made seminal contributions to understanding how memory CD4 T cells provide protection against influenza infection and how aging affects T cell function. Current research priorities include discovering new mechanisms used by memory CD4 T cells for effective immunity and defining age-associated defects to develop strategies to overcome them. Analysis of Dr. Swain's recent publications reveals a consistent focus on CD4 T cell memory checkpoints, the requirements for generating protective memory cells, and the impact of aging on immune responses. Her work demonstrates that persistent infection signals at effector checkpoints determine memory cell fates, and that age-associated B cells play critical roles in immune responses in the elderly. The research has significant implications for improving vaccine efficacy in aging populations. Among her notable honors are the NIH Merit Award (awarded twice), New York State Woman of Distinction, and the American Association of Immunologists Lifetime Achievement Award. She previously served as President of the American Association of Immunologists (2004) and has held numerous editorial positions including Deputy Editor of the Journal of Immunology. Dr. Swain actively mentors students through rotation projects focusing on CD4 T cell memory, cytotoxic CD4 effectors, and aging immunity. Her laboratory provides opportunities for postdoctoral researchers interested in T cell memory development and survival. She has served on numerous national advisory boards including the National Advisory Council on Aging (2008-2012) and the Scientific Advisory Board of the La Jolla Institute of Allergy and Immunology.

• Innate Immunity
• Inflammasome Biology
• Nucleic-Acid Sensing
• +6 more

Katherine A. Fitzgerald, PhD , is Professor and Vice Chair of Medicine at the University of Massachusetts Chan Medical School , where she also serves as Chief of the Division of Innate Immunity and holds the Worcester Foundation for Biomedical Research Chair III . She is cross-appointed in multiple graduate programs at the Morningside Graduate School of Biomedical Sciences , including Immunology and Microbiology, Translational Science, MD/PhD, and Post-baccalaureate Research Education. Education B.Sc. in Biochemistry, University College Cork, Ireland (1995) Ph.D. in Biochemistry, Trinity College Dublin, Ireland (1999) Research Focus Dr. Fitzgerald’s work is centered on the molecular basis of innate immunity , dissecting how nucleic-acid sensors, inflammasomes, and long non-coding RNAs orchestrate inflammatory responses during infection and in chronic inflammatory diseases. Her laboratory aims to translate these insights into therapeutic strategies for infectious, autoimmune, and autoinflammatory disorders. Scientific Honors Member, National Academy of Sciences (USA) Member, National Academy of Medicine (USA) Member, Royal Irish Academy Fellow, American Academy of Microbiology Thermo-Fisher Meritorious Career Award (2022) Saint Patrick’s Day Medal (2015) Milstein Award for Excellence in Interferon and Cytokine Research (2014) Leadership & Service Past President of the International Cytokine and Interferon Society, she serves on national advisory boards including NIAID’s Board of Scientific Councillors and the Massachusetts Center for Pathogen Readiness. Laboratory & Training Her Fitzgerald Lab (Program in Innate Immunity) welcomes graduate rotation students; interested applicants should contact Kate.Fitzgerald@umassmed.edu .

• Immunology
• Rheumatology
• Applied Immunology
• +8 more

Dr. Andrew Craig is an Associate Professor in the Department of Biomedical and Molecular Sciences at Queen's University, affiliated with the Faculty of Health Sciences and the Queen’s Cancer Research Institute. He holds cross appointments in the Cancer Biology & Genetics division and the Translational Institute of Medicine (TIME). He earned his PhD in Biochemistry from McGill University (1998) and completed postdoctoral training at Queen's University before joining the faculty in 2002. His research focuses on molecular mechanisms of cancer progression, immune suppression, and metastasis, with a particular emphasis on tumor suppressor miRNAs, actin-driven metastasis, and immunotherapy strategies. Education: PhD in Biochemistry, McGill University (1998) BSc in Biochemistry, Queen's University (1993) Research Interests: Dr. Craig’s work spans immunology, oncology, and cellular biology. Key areas include: Inflammatory mechanisms and inflammasomes Cancer immunotherapy and metastasis TGF-β signaling pathways MicroRNA biomarkers in lung cancer Actin-targeting compounds for cancer treatment Research Highlights: His lab has developed novel synthetic antibodies targeting TGF-β to improve chemotherapy efficacy in ovarian cancer models. Recent studies focus on functional genomic screening to identify vulnerabilities in inflammatory breast cancer and defining miRNA biomarkers in immunotherapy-treated patients. His work integrates advanced techniques like confocal microscopy and flow cytometry. Awards: Canadian Cancer Society Young Investigator Award (2011) Grants & Funding: Dr. Craig maintains continuous external funding for his research, supported by grants from agencies such as the Canadian Cancer Society and the Canadian Institutes of Health Research (CIHR). Labs & Affiliations: He leads the Craig Lab within the Department of Biomedical and Molecular Sciences and collaborates with the Queen’s Cancer Research Institute and Translational Institute of Medicine (TIME). His research bridges basic science and clinical translation, emphasizing preclinical models of disease and precision medicine approaches.

• Cancer Genomics
• Pan-Cancer Analysis
• Neuro-Immunology of Cancer
• +5 more

Dr. Ida Deichaite is an Assistant Adjunct Professor in the Department of Radiation Medicine and Applied Sciences at the University of California, San Diego. With a background in virology and molecular biology, she applies genomics analysis to identify susceptibility targets for aggressive cancers using a bed-to-bench approach that integrates real-world genomics with clinical data. Prior to her faculty appointment in November 2019, she collaborated with UCSD Moores Cancer Center leadership, private sector partners, and grant agencies to develop translational programs that resulted in FDA-approved therapeutics. Education B.Sc. in Horticulture, Hebrew University, Jerusalem (1983) M.Sc. in Virology, Weizmann Institute (1985, Cum Laude) Ph.D. in Molecular Biology, Princeton University (1991) Postdoctoral Training in Molecular Biology, Memorial Sloan Kettering Cancer Center (1993) Research Focus Dr. Deichaite's research program focuses on identifying actionable targets and mechanisms for oncology diagnostics and therapeutics. Her work spans cancer genomics, pan-cancer analyses, neuro-immunology of cancer, and translational oncology, with particular expertise in head and neck cancers, prostate cancer, and radiogenomics. She employs genomic analysis to overcome limitations of experimental models and accelerate clinical translation. Publication Focus Her recent publications demonstrate a strong focus on cancer biomarkers, immunotherapy response prediction, radiation toxicity mechanisms, and immune evasion in prostate cancer. Earlier work established foundations in molecular virology and protein biochemistry, while current research emphasizes clinical applications of genomics in oncology. Awards and Honors 1st Prize - Best Poster Presentation, International Cancer Education Conference (2018) Employee of the Year, UC San Diego (2014) Fellowship Award, Princeton University (1986) M.Sc. Cum Laude, Weizmann Institute (1985) Professional Contributions Dr. Deichaite contributed to the development of FDA-approved therapeutics including Daurismo (glasdegib) and INREBIC (fedratinib), and participated in high-value acquisitions such as VelosBio's acquisition by Merck. She maintains active collaborations across institutions and industry partners to advance translational oncology programs.

• Immunology
• Cell Biology
• Molecular Biology
• +5 more

Stephen Terry is a Research Associate in Physics with 146 citations and 7 research outputs, demonstrating significant contributions to interdisciplinary research spanning immunology, cell biology, and post-COVID-19 studies. His work aligns with UN Sustainable Development Goals related to health and well-being. Dr. Terry's research portfolio reveals expertise in multiple domains: Immune system aging patterns in relation to infectious diseases Post-COVID-19 respiratory complications and recovery mechanisms Cell membrane dynamics and protein function Molecular interactions between biological structures His research interests, derived from his publication fingerprint, prominently feature COVID-19 (100%), Dyspnea (100%), Post-COVID-19 conditions (54%), and various aspects of cell biology including Cell Kinetics, Maturation, Actin, Capping Phenomenon, and Dynamics (all 50%). This multidisciplinary approach bridges clinical medicine with fundamental biological research. Dr. Terry's publication record shows a strategic progression from fundamental cellular mechanisms (2021-2022) to clinical applications related to the global pandemic (2023-2024). His most recent work, published in high-impact journals including Immunity and Ageing and The Lancet family of journals, has received substantial attention with multiple articles covered by news outlets and widely shared across social media platforms. As a key collaborator in the PHOSP-COVID Study collaborative group and ISARIC4C Investigators, Dr. Terry participates in large-scale, multi-institutional research efforts addressing critical questions in post-viral syndromes. His work has accumulated significant citations, with his 2021 JACS paper receiving 36 citations, demonstrating the impact of his research across multiple disciplines.

Serdar UysalView profile

Assistant Professor

• Paratransgenesis
• Immunotherapy
• Protein Engineering
• +4 more

Asst. Prof. Serdar Uysal is affiliated with the Department of Biophysics at the Faculty of Medicine, Bezmialem Vakıf University. His research focuses on paratransgenesis, immunotherapy, and protein/microbial engineering, with applications against vector-borne diseases like malaria and in Chimeric Antigen Receptor (CAR) T-cell therapy for cancers such as multiple myeloma and acute lymphoblastic leukemia. His lab develops engineered microorganisms to produce synthetic antibodies and explores novel antibody scaffolds for CAR-T cell therapies. Education details are not explicitly stated in the text, but his institutional affiliation indicates advanced academic qualifications in biophysics or related fields. Research interests include malaria pathogenesis, phage display libraries for antibody fragment development, and optimizing CAR-T cell efficacy through alternative antibody scaffolds. His work addresses global health challenges, particularly in diseases with complex life cycles like malaria. He has advised 3 theses, though specific student names are not provided. His lab (Uysal Lab) contributes to translational research bridging basic science and clinical applications in immunotherapy. Publications: 18 entries reported in the Research Information System, with 774 WoS citations and an H-index of 9. He holds 1 intellectual property and has participated in 5 projects. Open-access contributions include 11 publications aligned with UN Sustainable Development Goals.

• Oncology
• Immunotherapy
• Clinical Trials
• +3 more

Salman Punekar, MD is a Clinical Instructor in the Department of Pulmonary, Critical Care & Sleep Medicine at the Yale School of Medicine. He specializes in oncology and clinical trials focused on innovative cancer therapies. Dr. Punekar’s research emphasizes immunotherapy, particularly CAR T-cell therapies and targeted molecular agents, with a focus on solid tumors and pancreatic cancer. He has contributed to multiple phase I/II clinical trials evaluating novel treatments such as RMC-6236 (RAS inhibitor), A2B530/A2B694 (logic-gated CAR T-cell therapies), and PRT3789 (SMARCA2 degrader). His work addresses treatment efficacy, safety, and biomarker analysis using circulating tumor DNA (ctDNA). Education: MD from Drexel University College of Medicine (2011). Research interests span molecular targeted therapies, immune-checkpoint inhibitors, and translational oncology. He collaborates on studies involving KRAS mutations (G12V/D), EGFR-driven NSCLC, and HLA loss of heterozygosity (LOH) in solid tumors. Dr. Punekar also investigates disparities in cancer care outcomes among ethnic/racial minority populations. Key publications from 2024-2025 highlight advancements in CAR T-cell engineering, RAS pathway inhibition, and SMARCA2 degradation strategies. His work bridges preclinical insights with clinical trial execution to advance personalized cancer medicine.

• CRISPR Technology
• Immunotherapy
• Cancer Research
• +3 more

Xiao Zhou is a Research Fellow at the Yale School of Medicine, where he focuses on advancing CRISPR-based technologies, immunotherapy, and cancer research. He holds a PhD from Boston University (2022) and contributes to interdisciplinary studies at the intersection of genetics, immunology, and virology. His work emphasizes multiplexed gene editing in immune cells, tumor immunology, and vaccine development against pathogens like SARS-CoV-2. Research Interests: Dr. Zhou’s research explores CRISPR applications in cellular engineering, immunotherapy strategies for cancer resistance, and the design of variant-specific vaccines. His studies often involve in vivo CRISPR screens to uncover therapeutic targets in CD8 T cells and regulatory T cell dynamics. Publications: His work spans CRISPR-mediated genome editing, CAR-T cell enhancements, and heterotypic vaccine responses. Recent studies highlight breakthroughs in Cas12a knock-in mice models and mechanisms of tumor immunity. Professional Background: As a Research Fellow, Zhou collaborates with teams advancing translational medicine and viral immunology. His contributions bridge basic science and clinical applications, with a focus on precision interventions in oncology and infectious diseases.

David KlenermanView profile

Professor

• Protein folding and misfolding
• Molecular basis of neurodegenerative disease
• Single molecule fluorescence
• +4 more

David Klenerman is a Professor of Molecular Medicine at the University of Cambridge, holding the Royal Society Chair since 2016. Previously, he was Professor of Biophysical Chemistry (2007–2016), Reader in Biophysical Chemistry (2004–2007), and Lecturer in the Department of Chemistry (1994–2004). His research focuses on biophysical methods applied to biomedical problems, including protein misfolding, neurodegenerative diseases, and high-speed DNA sequencing. He co-invented the Solexa (Illumina) sequencing technology and founded the biotech company Solexa. Research Interests: Protein folding/misfolding mechanisms Molecular basis of neurodegenerative diseases (Parkinson's, Alzheimer's) Single-molecule fluorescence microscopy Imaging adaptive immune responses Genomic technologies (DNA sequencing) Key Awards: 2022 Breakthrough Prize in Life Sciences 2021 Millennium Technology Prize 2018 Royal Medal (Royal Society) 2016 Royal Society Glaxo Wellcome Professorship 2012 Fellowship of the Royal Society Labs/Teams: Co-founder of Solexa (now Illumina), leading interdisciplinary research groups focused on biophysical techniques for biomedical applications. His work bridges chemistry, physics, and medicine, with applications in diagnostics and drug discovery.